The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The treatment of mood disorders has been the subject of intense study for more than half a century and has resulted in the discovery and availability of a number of compounds that have seen tremendous success in the management of major depression and anxiety-related disorders. In spite of this success, these drugs have not provided a complete therapeutic solution for all patients and this has revitalised the need for a greater understanding of the underlying molecular mechanisms and targets involved in these disorders. Elucidation of these novel targets will enable the development of a better class of compounds which could benefit a greater majority of the patient population and be devoid of the current side effect liabilities. Towards that end, this review examines, in detail, the prospect of one such target, the corticotropin-releasing factor system, as having an enhanced therapeutic profile with the potential of a broader range of efficacy with reduced side effect liabilities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965
Heim, C., & Nemeroff, C. B. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01157-x · Cited by 2,791
Epidemiology of women and depression
Kessler, R. (2003) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00426-3 · Cited by 2,006 · cited 1×
“It is also estimated that 25% of the population will experience a depressive episode at some time in their lives with women being twice as likely to be affected in any given year as men for reasons that are, as yet, not well understood [2].”
BackgroundSwanson, L. W., Sawchenko, P. E., Rivier, J., & Vale, W. W. (2008) · Neuroendocrinology · doi:10.1159/000123454 · Cited by 1,953
Nemeroff, C. B., Widerlöv, E., Bissette, G., Walléus, H., Karlsson, I., Eklund, K., Kilts, C. D., Loosen, P. T., & Vale, W. (1984) · Science · doi:10.1126/science.6334362 · Cited by 1,485 · cited 2×
“Postmortem studies, although not completely in agreement, have suggested that the elevated levels of CRF in the CSF of depressed patients, coupled with the decreased CRF receptor binding in the frontal cortex of suicide victims, is evidence that the CRF system is hyperactive in this disorder [153,158,280,281].”
BackgroundThe Biochemistry of Affective Disorders
Coppen, A. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1237 · Cited by 1,230 · cited 1×
“First was the hypothesis that depression was manifested through a defect in monoaminergic neurotransmission [16,17].”
BackgroundLewis, K., Li, C., Perrin, M. H., Blount, A., Kunitake, K., Donaldson, C., Vaughan, J., Reyes, T. M., Gulyas, J., Fischer, W., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121165198 · Cited by 925 · cited 6×
“UCN2 and UCN3 are much more selective for the CRF2 receptor subtype over the CRF1 receptor and have little or no Expert Opin.”
BackgroundInfluentialTimpl, P., Spanagel, R., Sillaber, I., Kresse, A., Reul, J. M. H. M., Stalla, G. K., Blanquet, V., Steckler, T., Holsboer, F., & Wurst, W. (1998) · Nature Genetics · doi:10.1038/520 · Cited by 919 · cited 1×
“CRF seems to play a major role in the maintenance of cocaine self-administration, and CRF1 receptor antagonists block stress-induced reinstatement of cocaine/heroin use [313-318]”
BackgroundSmith, G. W., Aubry, J.-M., Dellu, F., Contarino, A., Bilezikjian, L. M., Gold, L. H., Chen, R., Marchuk, Y., Hauser, C., Bentley, C. A., et al. (1998) · Neuron · doi:10.1016/s0896-6273(00)80491-2 · Cited by 892
Reyes, T. M., Lewis, K., Perrin, M. H., Kunitake, K. S., Vaughan, J., Arias, C. A., Hogenesch, J. B., Gulyas, J., Rivier, J., Vale, W. W., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051626398 · Cited by 887 · cited 5×
“UCN2 and UCN3 are much more selective for the CRF2 receptor subtype over the CRF1 receptor and have little or no Expert Opin.”
BackgroundInfluential
Cited by
Stress Hormone Regulation: Biological Role and Translation into Therapy
Holsboer, F., & Ising, M. (2010) · Annual Review of Psychology · doi:10.1146/annurev.psych.093008.100321 · Cited by 473
“…CRH in animal models, and the fact that human CRH binds at the CRHR1 with 15- fold higher affinity over CRHR2, led to the hypothesis that selective CRHR1 antagonists are promising drug candidates for the treatment of depression, anxiety, and other stress-related disorders (Grigoriadis 2005).”
BackgroundHolsboer, F., & Ising, M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.12.032 · Cited by 382
Hauger, R., Risbrough, V., Brauns, O., & Dautzenberg, F. (2006) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152706777950684 · Cited by 343
Role of CRF Receptor Signaling in Stress Vulnerability, Anxiety, and Depression
Hauger, R. L., Risbrough, V., Oakley, R. H., Olivares‐Reyes, J. A., & Dautzenberg, F. M. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05011.x · Cited by 217
Interaction of Stress, Corticotropin-Releasing Factor, Arginine Vasopressin and Behaviour
Beurel, E., & Nemeroff, C. B. (2014) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2014_306 · Cited by 64
“These findings supported the development of CRF receptor antagonists as a new therapeutic strategy for depression (Grigoriadis 2005).”
Background
Metadata
- Authors
- Grigoriadis, D. E.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2005-08
- Volume
- 9
- Issue
- 4
- Pages
- 651-684
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2163360377
- Cited by
- 75
- References
- 31
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders. https://app.cochat.ai/papers/10.1517/14728222.9.4.651
- The paper
- Grigoriadis, D. E. (2005). The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.9.4.651
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.